Loading
A phase 2 trial of Sapanisertib, Serabelisib, Paclitaxel / nab-paclitaxel in endometrial cancer, run by Faeth Therapeutics, now recruiting.
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer is a phase 2 interventional study registered as NCT06463028 by Faeth Therapeutics, with 40 participants planned, started 2024-12-12 and due to reach its primary completion in 2028-09. Interventions recorded: Sapanisertib, Serabelisib, Paclitaxel. Conditions listed: Endometrial Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Sapanisertib, Serabelisib.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer, Paclitaxel / nab-paclitaxel.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer, Paclitaxel / nab-paclitaxel.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer, Paclitaxel / nab-paclitaxel.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer, Paclitaxel / nab-paclitaxel.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/